A Participant- and Investigator--Blinded, Placebo- Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
Latest Information Update: 20 Jan 2026
At a glance
- Drugs OJR 520 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Novartis
Most Recent Events
- 02 Dec 2025 Planned primary completion date changed from 7 Jul 2027 to 19 Jul 2027.
- 02 Dec 2025 Status changed from not yet recruiting to recruiting.
- 26 Nov 2025 New trial record